Keratoconus Treatments

Keratoconus Treatment Options – Corneal Cross-Linking (CXL) and Intacs

Historically, there have been no options to slow the progression of Keratoconus. The primary treatment consisted of regular eye exams to adjust glasses and contact lens prescriptions. Properly-fitted hard contact lenses often provide the best attainable vision, but can be uncomfortable.

Furlong Vision Correction offers Corneal Cross-Linking (CXL) and Intacs, as separate or combined procedures for eligible candidates. After a thorough clinical review and evaluation of the FDA approved Avedro KXL and Photrexa protocol for Corneal Cross-Linking (CXL), Dr. Michael Furlong and Dr. Mona Sane are now offering CXL treatment to patients who have been diagnosed with progressive keratoconus and ectasia. CXL is an exciting procedure that employs a biochemical reaction to strengthen the collagen fibers and prevent progression or worsening of Keratoconus. Learn more. Intacs are ring segments that are placed within the cornea to flatten it and create a more uniform surface for improved contact lens fitting. They may improve uncorrected and corrected vision and reduce astigmatism.

If you have been diagnosed with Keratoconus or feel you have symptoms, we encourage you to make an appointment with Dr. Sane to understand the options you have to improve your vision and lifestyle. Furlong Vision Correction will submit treatment pre-authorization requests to your insurance carrier for approval and reimbursement.  If you have been diagnosed with keratoconus or suspect that you might have this condition, please contact our clinic at (800) 573-1010 to schedule an appointment for your consultation and testing.

View Video

Learn more about Keratoconus disease, causes and diagnosis.


We are:


about transforming your life through excellent eye care and exemplary service.


to providing you with the time and attention you deserve to make the right choice for your eyes. We will also treat you and your referring doctor with enthusiasm and integrity.